中医临床研究
中醫臨床研究
중의림상연구
CLINICAL JOURNAL OF CHINESE MEDICINE
2015年
6期
37-38
,共2页
顺尔宁%喘息性支气管炎%疗效评估
順爾寧%喘息性支氣管炎%療效評估
순이저%천식성지기관염%료효평고
Singulair%Asthmatic bronchitis%Curative effect evaluation
目的:探讨为喘息性支气管炎患儿应用顺尔宁治疗的临床疗效。方法:选取2013年09月—2014年10月我院收治的喘息性支气管炎患儿100例,按硬币法将其分成实验组50例,对照组50例,对照组病例应用雾化吸入普米克令舒吸入治疗,实验组病例在对照组治疗的基础上应用顺尔宁治疗,比较疗效。结果:实验组喘息性支气管炎患儿治疗效果优于对照组,实验组疾病治疗有效率为92.0%,咳喘缓解时间为(48.21±5.21)h,哮鸣音消失时间为(60.15±7.51)h,住院时间为(5.95±0.46) d,以上数据与对照组相比,差异有统计学意义(P<0.05)。结论:为喘息性支气管炎患儿应用顺尔宁治疗,效果满意,顺尔宁临床应用价值高,值得推广。
目的:探討為喘息性支氣管炎患兒應用順爾寧治療的臨床療效。方法:選取2013年09月—2014年10月我院收治的喘息性支氣管炎患兒100例,按硬幣法將其分成實驗組50例,對照組50例,對照組病例應用霧化吸入普米剋令舒吸入治療,實驗組病例在對照組治療的基礎上應用順爾寧治療,比較療效。結果:實驗組喘息性支氣管炎患兒治療效果優于對照組,實驗組疾病治療有效率為92.0%,咳喘緩解時間為(48.21±5.21)h,哮鳴音消失時間為(60.15±7.51)h,住院時間為(5.95±0.46) d,以上數據與對照組相比,差異有統計學意義(P<0.05)。結論:為喘息性支氣管炎患兒應用順爾寧治療,效果滿意,順爾寧臨床應用價值高,值得推廣。
목적:탐토위천식성지기관염환인응용순이저치료적림상료효。방법:선취2013년09월—2014년10월아원수치적천식성지기관염환인100례,안경폐법장기분성실험조50례,대조조50례,대조조병례응용무화흡입보미극령서흡입치료,실험조병례재대조조치료적기출상응용순이저치료,비교료효。결과:실험조천식성지기관염환인치료효과우우대조조,실험조질병치료유효솔위92.0%,해천완해시간위(48.21±5.21)h,효명음소실시간위(60.15±7.51)h,주원시간위(5.95±0.46) d,이상수거여대조조상비,차이유통계학의의(P<0.05)。결론:위천식성지기관염환인응용순이저치료,효과만의,순이저림상응용개치고,치득추엄。
Objective:To investigate the clinical effect of treatment for children with asthmatic bronchitis application singulair. Methods:From 2013 October 09 months to 2014 in our hospital 100 cases of children with asthmatic bronchitis, press the coin method divided into the experimental group 50 cases, control group 50 cases, control group cases application of Pulmicort Respules inhalation in the treatment of montelukast treatment, used in the experimental group were the basis of treatment in control group, comparison curative effect. Results:The experimental group is better than children with asthmatic bronchitis curative effect in control group, the effective rate in experimental group disease treatment is 92%, cough relief time was (48.21 ± 5.21) h, wheeze disappeared time of (60.15 ± 7.51) h, the time of hospitalization for (5.95 ±0.46) d, the above data compared with the control group, the difference was statistically significant (P<0.05). Conclusion:For asthmatic bronchitis in children with montelukast treatment application, effect satisfaction, Singulair high clinical application value, worthy of promotion.